Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Neutral

B

Aerovate Therapeutics, Inc. Common Stock (AVTE)

Pharmaceutical Preparations

https://www.aerovatetx.com

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.

930 WINTER STREET, SUITE M-500
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/30/2021

Market Cap

52,394,876

Shares Outstanding

27,670,000

Weighted SO

27,668,887

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

ADAG --.--%

ACRV --.--%

RZLT --.--%

ANTX --.--%

ANEB --.--%

OPT --.--%

MLYS --.--%

Beta

1.0210

Last Div

0.0000

Range

1.25-32.415

Chg

0.0250

Avg Vol

1205483

Mkt Cap

52394876

Exch

NASDAQ

Country

US

Phone

617 443 2400

DCF Diff

0.9185

DCF

0.8665

Div Yield

0.0000

P/S

385.2564

EV Multiple

-0.2338

P/FV

0.5529

Div Yield %

0.0000

P/E

-0.5935

PEG

0.0162

Payout

0.0000

Current Ratio

6.5076

Quick Ratio

6.5076

Cash Ratio

1.8254

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

13993.8991

CCC

-13993.8991

Gross Margin

0.1985

Op Margin

-692.7721

Pretax Margin

-646.1838

Net Margin

-646.5956

Eff Tax Rate

-0.0002

ROA

-0.7873

ROE

-0.8365

ROCE

-0.9952

NI/EBT

1.0006

EBT/EBIT

0.9328

EBIT/Rev

-692.7721

Debt Ratio

0.0061

D/E

0.0072

LT Debt/Cap

0.0022

Total Debt/Cap

0.0072

Int Coverage

-84.1975

CF/Debt

-109.4229

Equity Multi

1.1832

Rec Turnover

0.0000

Pay Turnover

0.0261

Inv Turnover

0.0000

FA Turnover

0.1594

Asset Turnover

0.0012

OCF/Share

-2.5914

FCF/Share

-2.5947

Cash/Share

3.6237

OCF/Sales

-547.9191

FCF/OCF

1.0013

CF Coverage

-109.4229

ST Coverage

-156.8779

CapEx Coverage

-776.2188

Div&CapEx Cov

-776.2188

P/BV

0.5529

P/B

0.5529

P/S

385.2564

P/E

-0.5935

P/FCF

-0.7022

P/OCF

-0.7004

P/CF

-0.7004

PEG

0.0162

P/S

385.2564

EV Multiple

-0.2338

P/FV

0.5529

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Mar 23, 22:59 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders GlobeNewswire Inc. Mar 17, 23:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NHHS, KVAC, AMPS, AVTE GlobeNewswire Inc. Feb 25, 23:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NVRO, LGTY, AVTE, PLYA Benzinga Feb 24, 23:43 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - CCNE, LGTY, AVTE, PLYA GlobeNewswire Inc. Jan 27, 01:29 SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MHLD, IPG, AVTE on Behalf of Shareholders GlobeNewswire Inc. Nov 05, 23:53 INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE GlobeNewswire Inc. Nov 20, 16:45 Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension GlobeNewswire Inc. Nov 20, 16:45 Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Revenue Product Segmentation